$IMNM News

Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026

William Blair Initiates Coverage On Immunome with Outperform Rating

Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?

Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues

Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors

Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32

HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Truist Securities Maintains Buy on Immunome, Raises Price Target to $38

Wedbush Maintains Outperform on Immunome, Raises Price Target to $35

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors